Advanced Proteome Therapeutics Corporation
TSX VENTURE : APC

Advanced Proteome Therapeutics Corporation

November 17, 2008 09:00 ET

Advanced Proteome Therapeutics Makes Major Advance in Technology Development

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 17, 2008) - Advanced Proteome Therapeutics Corporation (TSX VENTURE:APC) is pleased to announce that its subsidiary Advanced Proteome Therapeutics Inc. (APT) has achieved a major advance in the development of its core, proprietary technology, kinetic labelling libraries.

The Company has produced kinetic labelling libraries in order to screen protein targets for sites along their surfaces to which therapeutic enhancing entities, diagnostic agents and other commercially viable entities can be specifically attached to form protein conjugates. Such conjugates have been constructed to deal with the difficulties of deploying "bare" proteins as therapeutics, which have become a growing and important class of drugs, but have severe limitations. The addition of appropriate appendages (e.g., polyethylene glycol chains) to therapeutic proteins have improved their duration of action and other pharmacokinetic properties, and in several instances have resulted in blockbuster drugs exceeding billions of dollars in sales, with many promising drugs still in development.

Technologies that can generate homogeneous protein conjugates and avoid the problems associated with heterogeneous mixtures such as potential immune reactions and toxicities, are much preferred by regulatory agencies. However, technologies designed to exploit the chemical modification of proteins to give homogeneous conjugates through site-specific attachments are lacking. APT has developed a platform technology to probe proteins for specific sites of attachment at which the target protein and the active agent can be combined to give a single homogeneous substance.

The libraries represent core technology, aimed at facilitating site-selective linkage of various "payloads" to improve the performance of commercially viable proteins. Although the site-selective attachment of library entities to high value protein therapeutics has been demonstrated by APT by screening pools (mixtures), these first generation libraries have now been considerably improved.

In the new generation of libraries, methodologies have been introduced to enable the screening of a target protein against thousands of library members that have been separated spatially to avoid testing mixtures. These advances have resulted in the construction of libraries free of impurities and the multiple interactions associated with mixtures that can complicate analysis. The current advance will simplify discovery of the best candidates for site-specific labelling. in a much shorter timeframe than occurred with first generation libraries. Screening times for the discovery and identification of promising candidates for site-selective labelling of commercially viable proteins that had extended over several months, and involved multiple rounds of synthesis and analysis, have been reduced to just a few short weeks using a single screen.

Alexander (Allen) Krantz stated that, "The Company believes that such library optimization, combined with the technology's applicability to natural (unmutated) proteins, and its potential for site-selective attachments at a variety of points along the protein surface, confer important competitive advantages that differentiate APT from the competition. The Company anticipates that the combination of attributes makes APT technology appealing to industry professionals because of its novelty, utility and practicality, and the Company is now in a much stronger position to attract Corporate partners and promote joint commercial efforts."

About APC

APC's primary corporate primary mission is to apply its proprietary drug delivery and drug redevelopment technologies to produce new, improved versions of therapeutic proteins and pioneer the emerging field of protein-site targeting. The market for diagnostics and therapeutic proteins and peptides is expected to surpass more than 50 Billion USD by the year 2010 and is the fastest growing segment of the pharmaceutical market. Future growth however depends largely on the industry overcoming a number of hurdles, including drug delivery challenges and the need for homogeneous conjugates that APC is attempting to address.

The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.

Contact Information

  • Encompass Communications Inc.
    (604) 630-0770 or Toll Free: 1-877-566-6592